Renal Cell Carcinoma Clinical Trial
Official title:
An Open-label, Non-comparative, Treatment Protocol for the Use of BAY 43-9006 (Sorafenib) in Patients With Advanced Renal Cell Carcinoma
This is the early access programme (EAP) of sorafenib in the indication of advanced renal cell carcinoma (RCC). The study is to evaluate the efficacy and safety of sorafenib in patients with advanced RCC.
Renal cell carcinoma (RCC) accounts for approximately 3 % of all cancers. RCC can be cured
if diagnosed and treated when still localized to the kidney or immediate surrounding
tissues. Since most of the RCC tumours are diagnosed when still localized, approximately 40
% of all patients survive 5 years. The median survival of Stage IV RCC after diagnosis is 8
to 12 months and the 5-year survival is less than 10 %. Surgery has been the primary therapy
for RCC for more than a century. Until recently, metastatic disease has been refractory to
any systemic therapy. Despite recent advances in immunotherapy (e.g. Interferon and
Interleukin-2), the response rates remain low (15 %) and few patients experience durable
remission. Surgical and radiation therapies for Stage IV disease are generally limited to
palliation of symptoms. For the majority of patients, metastatic RCC is incurable and
patients should be considered candidates for clinical trials when appropriate. In summary,
the available therapies for advanced unresectable and/or metastatic RCC have limited
clinical values, with response rates ranging from 6-20 % and little impact on the natural
history of the disease. Furthermore, the toxicities associated with these agents can be
severe, requiring careful patient selection, and this dramatically decreases the number of
patients who may benefit from therapy. Advanced RCC remains incurable and the need for more
effective therapies is high.
This is a non-randomized, open-label treatment protocol for patients with advanced RCC.
Patients will be treated with 400 mg oral sorafenib twice a day on a continuous. Patients in
this protocol may continue to be treated with sorafenib as a single agent until any of the
following criteria for drug or protocol discontinuation is reached:
1. Progression of disease.
2. The patient is unlikely to benefit from further treatment with sorafenib as judged by
the Investigator.
3. Intolerable toxicity of the drug.
4. Withdrawal of consent for any reason.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04987203 -
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
|
Phase 3 | |
Recruiting |
NCT06391879 -
Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Recruiting |
NCT04623502 -
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
|
N/A | |
Completed |
NCT02853344 -
Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
|
Phase 2 | |
Terminated |
NCT04088500 -
A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT05070637 -
Circulating Tumor Cell Reducing No-touch Nephrectomy
|
N/A | |
Active, not recruiting |
NCT03634540 -
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
|
Phase 2 | |
Not yet recruiting |
NCT06049030 -
A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01358721 -
Phase I Biomarker Study (BMS-936558)
|
Phase 1 | |
Active, not recruiting |
NCT04503148 -
Anesthesia and Cancer Study: Renal Cell Carcinoma
|
N/A | |
Completed |
NCT02386826 -
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
|
Phase 1 | |
Not yet recruiting |
NCT05808608 -
A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03323710 -
Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT02787915 -
DC1s-CTL Cellular Therapy for Renal Cell Carcinoma
|
Phase 1/Phase 2 |